<div id="readability-page-1">09:14 AM EST, 01/06/2026 (MT Newswires) -- Health care stocks were rising premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF ( XLV ) and iShares Biotechnology ETF (IBB) up 0.3%.Alumis ( ALMS ) stock surged by more than 133% after the company said its investigational oral drug envudeucitinib achieved &#34;superior&#34; skin clearance compared with placebo in two phase 3 trials in patients with moderate to severe plaque psoriasis.GSK (GSK) shares were up more than 3% after the company said Japan's Ministry of Health, Labour and Welfare has approved Exdensur as a treatment for severe bronchial asthma and chronic rhinosinusitis with nasal polyps.Alkermes ( ALKS ) stock was up more than 3% after the company said the US Food and Drug Administration granted breakthrough therapy designation to alixorexton for the treatment of narcolepsy type 1, a neurological disorder. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

葛兰素史克

阿尔凯默斯

医疗保健股票在周二盘前上涨，State Street Health Care Select Sector SPDR ETF (XLV) 和 iShares Biotechnology ETF (IBB) 上涨了 0.3%。Alumis (ALMS) 在其药物 envudeucitinib 在银屑病试验中显示出优越结果后，股价飙升超过 133%。GSK (GSK) 的股价在日本批准 Exdensur 用于重度哮喘后上涨超过 3%。Alkermes (ALKS) 在获得 FDA 对 alixorexton 用于 1 型嗜睡症的突破性疗法认证后，股价也上涨超过 3%

板块更新：医疗保健类股在周二盘前上涨